From Weight Loss to Legal Loss: How Wegovy Exposed a Hidden Patent Exception
GRUR International · 27.07.2026 · 75 (8) · 730-739
DOI: 10.1093/grurint/ikag041 ↗Kurz gefasst
Fachartikel in der Zeitschrift GRUR International, online erschienen am 15.05.2026. Verfasst von Peter Ganea.
Abstract (Originalsprache)
This article examines the US framework for pharmaceutical compounding under Secs. 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), and how it interacts with pharmaceutical patent protection. It explores how, once a patented drug appears on the FDA’s shortage list, pharmacies and so-called outsourcing facilities may supply substantial market volumes with compounded versions of ‘essentially a copy’ of such drug. This article evaluates the legal implications of this regulatory gap and situates the US model within the broader international framework governing drug approval, compounding, and patent rights, and outlines potential – though politically unlikely – avenues for reform.
Zitieren
APA
Ganea, P. (2026). From Weight Loss to Legal Loss: How Wegovy Exposed a Hidden Patent Exception. GRUR International, 75(8), 730-739. https://doi.org/10.1093/grurint/ikag041
Vancouver
Ganea P. From Weight Loss to Legal Loss: How Wegovy Exposed a Hidden Patent Exception. GRUR International. 2026;75(8):730-739. doi:10.1093/grurint/ikag041
BibTeX
@article{Ganea2026,
author = {Ganea, Peter},
title = {From Weight Loss to Legal Loss: How Wegovy Exposed a Hidden Patent Exception},
journal = {GRUR International},
year = {2026},
volume = {75},
number = {8},
pages = {730--739},
doi = {10.1093/grurint/ikag041}
}
EUVIMED